A Phase 2 interventional study of Nintedanib and Pirfenidoneone in Pulmonary Fibrosis, sponsored by Boehringer Ingelheim. Completed at 4 sites in Japan. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2017-03-06.
Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Pulmonary Fibrosis with a site in Japan — 2 open to participants now, 4 under way, 3 of them phase 3. Pulmonary Fibrosis · Japan.
Among the 11 studies in Pulmonary Fibrosis with a site in Japan, this one is the 10th largest by enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2011, is one of 4 in phase 2, and was the 3rd registered.
342 studies on the registry are indexed under Pulmonary Fibrosis; 98 are open to participants now.
Browse Pulmonary Fibrosis studies →2 of the 11 studies in Pulmonary Fibrosis with a site in Japan are open now. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in Japan, United States, Argentina and 24 more countries
Bristol-Myers Squibb · Sites in Japan
Ages 18+
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 71 Pulmonary Fibrosis studies recruiting now, 41 (58%) set no upper age limit and 4 (6%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 6
First in 2011; this study’s year is marked. 3 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 59 across 212 interventional studies indexed under Pulmonary Fibrosis.
Median enrollment 459 across the 10 interventional studies, 40 across the 1 observational. Of the 7 that completed or were terminated, 6 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 11 have an industry lead sponsor. The 5 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Boehringer Ingelheim has 9 studies filed under Pulmonary Fibrosis — fewer than ten, so there is no comparison to draw.
1 of the studies in Pulmonary Fibrosis with a site in Japan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07722507Bristol-Myers SquibbAntifibrotic Therapy Decision-Making in Pulmonary Fibrosis | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Pulmonary Fibrosis with a site in Japan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary objective of this study is to investigate the long-term tolerability and safety profile of BIBF 1120 on top of pirfenidone treatment in patients with Idiopathic Pulmonary Fibrosis who have completed a prior clinical trial of BIBF 1120 (1199.31).
Secondary objectives are to assess effects on some efficacy criteria during long term treatment with BIBF 1120 on top of pirfenidone.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
For female: Pregnant women or women who are breast feeding or of child bearing potential not using a highly effective method of for both at least 4 weeks prior to enrolment and 10 weeks after last study drug intake.
For male: Sexually active males not committing to using condoms both during the course of the study and ten weeks after last study drug intake (except if their partner is not of ).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Nintedanib · Drug: Pirfenidoneone
150 mg bid
Existing treatment
Incidence of Overall Adverse Events
Incidence (Number of patients) of Adverse events (AEs) over the course of treatment period including serious adverse events (SAEs), AEs leading to discontinuation of study medication, and fatal AEs.
Time frame: First drug administration until end of treatment, up to 5 years
Annual Rate of Decline in Forced Vital Capacity (FVC).
The adjusted annual rate of decline in Forced Vital Capacity (FVC). The means presents actually the adjusted rate based on a random coefficient regression with fixed effects for gender, age, height and random effect of patient specific intercept and time. Within-patient errors are modelled by an Unstructured variance-covariance matrix. Inter-individual variability is modelled by a Variance-Components variance-covariance matrix. The result for Annual rate of decline (ROD) in FVC should be interpreted with caution and along with descriptive statistics, because inferences used for this analysis might not be valid as suggested by skewed distribution of the data.
Time frame: Baseline and every 8 weeks after drug administration until end of treatment, up to 5 years
Annual Rate of Decline in Haemoglobin (Hb) Corrected Diffusing Capacity of the Lung for Carbon Monoxide (DLCO)
Adjusted annual rate of decline in Hb corrected DLCO. The means presents actually adjusted rate based on random coefficient regression with fixed effects for gender, age, height \& random effect of patient specific intercept \& time. Within-patient errors are modelled by Unstructured variance-covariance matrix.Inter-individual variability is modelled by a variance-Components variance-covariance matrix. mmHg: millimeters of mercury
Time frame: Baseline & every 8 weeks after drug administration until end of treatment, up to 5 years
Acute Exacerbations of IPF: Risk (Incidence Rate) of Acute Exacerbations of IPF.
The risk (incidence rate calculated as number of patients with at least 1 exacerbation, divided by the total time at risk ×100) of acute exacerbation of IPF.
Time frame: First drug administration until end of treatment, up to 5 years
Percentage of Patient With First Occurrence of Acute Exacerbations of Idiopathic Pulmonary Fibrosis (IPF) Until Week 234.
The percentage of patient having first acute exacerbation of Idiopathic Pulmonary Fibrosis (IPF) based on investigator reported adverse events until week 234.
Time frame: Week 234
| Milestone | Nintedanib |
|---|---|
| Started | 20 |
| Completed | 6 |
| Not completed | 14 |
| Withdrew: Adverse event | 12 |
| Withdrew: Protocol violation | 2 |
Incidence (Number of patients) of Adverse events (AEs) over the course of treatment period including serious adverse events (SAEs), AEs leading to discontinuation of study medication, and fatal AEs.
| participants | Nintedanib |
|---|---|
| AEs leading to discontinuation of trial drug | 12 |
| Fatal | 8 |
| Severe AEs | 11 |
The adjusted annual rate of decline in Forced Vital Capacity (FVC). The means presents actually the adjusted rate based on a random coefficient regression with fixed effects for gender, age, height and random effect of patient specific intercept and time. Within-patient errors are modelled by an Unstructured variance-covariance matrix. Inter-individual variability is modelled by a Variance-Components variance-covariance matrix. The result for Annual rate of decline (ROD) in FVC should be interpreted with caution and along with descriptive statistics, because inferences used for this analysis might not be valid as suggested by skewed distribution of the data.
| (mililitre (mL)/year) | Nintedanib |
|---|---|
| Annual Rate of Decline in Forced Vital Capacity (FVC). | -233.3 ± 72.59 |
Adjusted annual rate of decline in Hb corrected DLCO. The means presents actually adjusted rate based on random coefficient regression with fixed effects for gender, age, height \& random effect of patient specific intercept \& time. Within-patient errors are modelled by Unstructured variance-covariance matrix.Inter-individual variability is modelled by a variance-Components variance-covariance matrix. mmHg: millimeters of mercury
| mL/Minute(min)/mmHg per year | Nintedanib |
|---|---|
| Annual Rate of Decline in Haemoglobin (Hb) Corrected Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) | -1.3 ± 0.26 |
The risk (incidence rate calculated as number of patients with at least 1 exacerbation, divided by the total time at risk ×100) of acute exacerbation of IPF.
| patients per 100 patient-year | Nintedanib |
|---|---|
| Acute Exacerbations of IPF: Risk (Incidence Rate) of Acute Exacerbations of IPF. | 19.2 (8.29 to 37.82) |
The percentage of patient having first acute exacerbation of Idiopathic Pulmonary Fibrosis (IPF) based on investigator reported adverse events until week 234.
| percentage of participants | Nintedanib |
|---|---|
| Failure (Week 234) | 40.0 |
| Censored (Week 234) | 60.0 |
Collected over First drug administration until end of treatment, up to 5 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nintedanib | — | 16/20 (80%) | 19/20 (95%) |
| Event | Nintedanib |
|---|---|
| Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders | 13/20 |
| Dyspnoea exertionalRespiratory, thoracic and mediastinal disorders | 4/20 |
| CholecystitisHepatobiliary disorders | 2/20 |
| PneumoniaInfections and infestations | 2/20 |
| Respiratory tract infectionInfections and infestations | 2/20 |
| Decreased appetiteMetabolism and nutrition disorders | 2/20 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 2/20 |
| Deep vein thrombosisVascular disorders | 2/20 |
| Acute myocardial infarctionCardiac disorders | 1/20 |
| Right ventricular failureCardiac disorders | 1/20 |
| Event | Nintedanib |
|---|---|
| DiarrhoeaGastrointestinal disorders | 13/20 |
| NauseaGastrointestinal disorders | 12/20 |
| ConstipationGastrointestinal disorders | 8/20 |
| NasopharyngitisInfections and infestations | 7/20 |
| Decreased appetiteMetabolism and nutrition disorders | 7/20 |
| HypertensionVascular disorders | 6/20 |
| VomitingGastrointestinal disorders | 5/20 |
| Weight decreasedInvestigations | 5/20 |
| Abdominal painGastrointestinal disorders | 4/20 |
| InsomniaPsychiatric disorders | 4/20 |
Treated set (TS): This analysis set included all patients who were given study medication and were documented to have taken at least one dose of the trial medication.
| Age, Continuous(Years) | Nintedanib |
|---|---|
| Mean | 65.8 ± 9.5 |
| Gender(Participants) | Nintedanib |
|---|---|
| Female | 6 |
| Male | 14 |
The record gives a start of Sep 2011, a primary completion of Oct 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2017, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nintedanib